Fotemustine
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Summary
Fotemustine is an alkylating agent used in the treatment of metastatic melanoma.
- Generic Name
- Fotemustine
- DrugBank Accession Number
- DB04106
- Background
Not Available
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 315.69
Monoisotopic: 315.0750854 - Chemical Formula
- C9H19ClN3O5P
- Synonyms
- (+-)-Diethyl (1-(3-(2-chloroethyl)-3-nitrosoureido)ethyl)phosphonate
- (±)-DIETHYL (1-(3-(2-CHLOROETHYL)-3-NITROSOUREIDO)ETHYL)PHOSPHONATE
- Diethyl-1-(3-(2-chloroethyl)-3-nitrosoureido)ethylphosphonate
- Fotemustina
- Fotemustine
- Fotemustinum
- Mustoforan
- PHOSPHONIC ACID, (1-((((2-CHLOROETHYL)NITROSOAMINO)CARBONYL)AMINO)ETHYL)-, DIETHYL ESTER
- PHOSPHONIC ACID, P-(1-((((2-CHLOROETHYL)NITROSOAMINO)CARBONYL)AMINO)ETHYL)-, DIETHYL ESTER
- External IDs
- S 10036
- S-10036
- S10036
- Servier-10036
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Metastatic melanoma •••••••••••• ••••••• ••• ••••••••• •••••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism AThioredoxin reductase 1, cytoplasmic inhibitorHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAmbroxol The risk or severity of methemoglobinemia can be increased when Fotemustine is combined with Ambroxol. Articaine The risk or severity of methemoglobinemia can be increased when Fotemustine is combined with Articaine. Benzocaine The risk or severity of methemoglobinemia can be increased when Fotemustine is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Fotemustine is combined with Benzyl alcohol. Bupivacaine The risk or severity of methemoglobinemia can be increased when Fotemustine is combined with Bupivacaine. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- ATC Codes
- L01AD05 — Fotemustine
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- GQ7JL9P5I2
- CAS number
- 92118-27-9
- InChI Key
- YAKWPXVTIGTRJH-UHFFFAOYSA-N
- InChI
- InChI=1S/C9H19ClN3O5P/c1-4-17-19(16,18-5-2)8(3)11-9(14)13(12-15)7-6-10/h8H,4-7H2,1-3H3,(H,11,14)
- IUPAC Name
- diethyl (1-{[N-(2-chloroethyl)-N'-oxohydrazinecarbonyl]amino}ethyl)phosphonate
- SMILES
- CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O
References
- Synthesis Reference
- US4567169
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0252474
- PubChem Compound
- 46936889
- PubChem Substance
- 46505097
- ChemSpider
- 94600
- ChEBI
- 131852
- ChEMBL
- CHEMBL549386
- ZINC
- ZINC000005859934
- Wikipedia
- Fotemustine
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data3 Completed Treatment Malignant Melanoma / Recurrent Melanoma 1 somestatus stop reason just information to hide 3 Terminated Treatment Intraocular Melanoma / Metastatic Cancer 1 somestatus stop reason just information to hide 3 Unknown Status Treatment Brain Metastases 1 somestatus stop reason just information to hide 2 Completed Treatment Glioblastoma Multiforme (GBM) 1 somestatus stop reason just information to hide 2 Completed Treatment Malignant Melanoma 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Powder, for solution Intravenous 208 MG Injection, powder, for solution Intravenous 200 mg/4ml Solution Intravenous 208 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP 1.28 Chemaxon pKa (Strongest Acidic) 11.81 Chemaxon pKa (Strongest Basic) -5.4 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 97.3 Å2 Chemaxon Rotatable Bond Count 9 Chemaxon Refractivity 71.42 m3·mol-1 Chemaxon Polarizability 28.72 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9709 Blood Brain Barrier + 0.7425 Caco-2 permeable - 0.5823 P-glycoprotein substrate Non-substrate 0.6191 P-glycoprotein inhibitor I Non-inhibitor 0.6195 P-glycoprotein inhibitor II Non-inhibitor 0.755 Renal organic cation transporter Non-inhibitor 0.8932 CYP450 2C9 substrate Non-substrate 0.7887 CYP450 2D6 substrate Non-substrate 0.8071 CYP450 3A4 substrate Non-substrate 0.5117 CYP450 1A2 substrate Non-inhibitor 0.7836 CYP450 2C9 inhibitor Non-inhibitor 0.7355 CYP450 2D6 inhibitor Non-inhibitor 0.8882 CYP450 2C19 inhibitor Non-inhibitor 0.67 CYP450 3A4 inhibitor Non-inhibitor 0.8724 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8853 Ames test AMES toxic 0.9107 Carcinogenicity Carcinogens 0.7102 Biodegradation Not ready biodegradable 0.8846 Rat acute toxicity 3.1868 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.6413 hERG inhibition (predictor II) Non-inhibitor 0.8627
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsThioredoxin reductase 1, cytoplasmic
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Reduces disulfideprotein thioredoxin (Trx) to its dithiol-containing form (PubMed:8577704). Homodimeric flavoprotein involved in the regulation of cellular redox reactions, growth and differentiation. Contains a selenocysteine residue at the C-terminal active site that is essential for catalysis (Probable). Also has reductase activity on hydrogen peroxide (H2O2) (PubMed:10849437)
- Specific Function
- FAD binding
- Gene Name
- TXNRD1
- Uniprot ID
- Q16881
- Uniprot Name
- Thioredoxin reductase 1, cytoplasmic
- Molecular Weight
- 70905.58 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y, Wang S, Qiu Y, Chen Y, Zhu F: TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751. [Article]
Drug created at June 13, 2005 13:24 / Updated at August 26, 2024 19:24